BPC-157 (sometimes searched as “BP 157”) is a synthetic peptide made of 15 amino acids, derived from a protective protein naturally found in human gastric juice. The name stands for Body Protection Compound, and it was first described in 1993 by researchers who identified it in the stomach and observed its healing properties. Since then, it has become one of the most discussed peptides in fitness, biohacking, and regenerative medicine circles, largely because of animal studies showing it can accelerate healing in tendons, gut tissue, and even brain injuries. However, it is not approved for human use by the FDA, and nearly all of the evidence comes from rodent and cell studies.
Where BPC-157 Comes From
Your stomach naturally produces a protein that helps protect and repair the lining of your gastrointestinal tract. BPC-157 is a fragment of that protein, a chain of exactly 15 amino acids with the sequence GEPPPGKPADDAGLV. Its molecular weight is 1,419 daltons, making it a very small peptide. The version used in research and sold as a supplement is synthetically manufactured to replicate this natural fragment. It’s sometimes called “stable gastric pentadecapeptide” because, unlike many peptides, it resists breakdown in stomach acid.
How It Works in the Body
BPC-157’s primary mechanism involves promoting the growth of new blood vessels, a process called angiogenesis. In lab studies, it increases the density of blood vessels both in living animals and in cell cultures. It does this by ramping up production of a key receptor on the surface of blood vessel cells (VEGFR2), which triggers a signaling chain that tells the body to build new vasculature. More blood flow to damaged tissue means faster delivery of oxygen, nutrients, and immune cells, all of which speed up repair.
Beyond blood vessel growth, the peptide also stimulates the production of collagen (the structural protein in tendons, skin, and gut lining) and activates growth factor receptors on the cells responsible for building connective tissue. It also interacts with the nitric oxide system, which plays a role in blood flow regulation and tissue protection.
Tendon and Ligament Repair
The strongest body of animal research involves musculoskeletal injuries. In rats with completely severed Achilles tendons, BPC-157 treatment accelerated healing by boosting the proliferation of tendon cells and increasing collagen production. The healed tendons could withstand greater force before failing, and the animals regained function faster, as measured by standardized movement tests over 14 days. In one study, these structural improvements persisted through a 21 to 72 day observation window.
Other rat studies have shown similar results for ligament injuries. Surgically cut knee ligaments healed faster with BPC-157 treatment. Perhaps most notably, the peptide appeared to improve tendon-to-bone healing even when corticosteroids were present, which is significant because steroids typically impair tissue repair. This combination of findings is why BPC-157 has attracted so much attention from athletes and people recovering from orthopedic injuries.
Gut Healing Properties
Given its origins in gastric juice, it’s not surprising that BPC-157 shows strong effects on the digestive tract. In animal models, it has demonstrated both anti-ulcer properties and the ability to reduce inflammation in conditions resembling inflammatory bowel disease. It appears to work by protecting the gut lining, stimulating the production of growth factors that rebuild damaged tissue, and promoting early collagen formation in wounds. A Phase II clinical trial investigated its use for inflammatory bowel disease under the drug code PL 14736, though this line of research has not advanced to market approval.
Effects on the Brain and Nervous System
Animal research has also explored BPC-157’s effects on the central nervous system, with some striking results. In mice with traumatic brain injuries caused by a controlled impact, BPC-157 treatment reduced brain swelling, decreased the severity of bleeding inside the skull, and improved survival rates over a 24-hour period following injury.
The peptide also appears to interact with two of the brain’s most important chemical messenger systems. In the dopamine system, it counteracts a wide range of disruptions, including the effects of receptor blockade, overstimulation, and damage to the brain regions that produce dopamine. In the serotonin system, it increases serotonin release in specific brain areas and has shown antidepressant-like effects in rat models of depression, including both acute stress tests and chronic unpredictable stress models. It also counteracted serotonin syndrome (a dangerous state of serotonin overload) in animal experiments.
These neurological findings are preliminary and limited to animal models, but they suggest the peptide’s effects extend well beyond simple tissue repair.
Human Evidence Is Extremely Limited
Despite decades of animal research, BPC-157 has barely been tested in humans. A single Phase I clinical trial was registered on ClinicalTrials.gov to evaluate the basic safety and absorption of oral BPC-157 in healthy volunteers. The trial’s primary goal was simply to check for adverse events and measure how the peptide moves through the bloodstream (how quickly it peaks, how long it lasts). Its status is listed as “unknown,” meaning no results have been published or updated. No Phase II or Phase III efficacy trials in humans have been completed for any condition.
This is the central limitation of BPC-157. The animal data is extensive and often impressive, but translating rodent results to humans is unreliable. Peptides can behave very differently in human physiology, and dosing, safety, and effectiveness all remain unverified.
Regulatory Status and Safety Concerns
BPC-157 is not approved by the FDA for any medical use. The agency has specifically flagged it as a bulk drug substance that may present significant safety risks when used in compounded medications. The FDA’s concerns center on three issues: the potential for immune reactions (the body attacking the peptide as foreign), difficulties in ensuring purity during manufacturing, and the fundamental lack of safety data in humans. In the agency’s own words, it “lacks sufficient information to know whether the drug would cause harm when administered to humans.”
Despite this, BPC-157 is widely available through online peptide vendors and some compounding pharmacies. People typically use it as a subcutaneous injection near the site of an injury or take it orally for gut-related issues. Because it exists in a regulatory gray area, quality control varies enormously between suppliers. Contamination, inaccurate dosing, and degraded product are real risks with unregulated peptides.
One theoretical concern that researchers have raised involves its potent ability to grow new blood vessels. While angiogenesis is beneficial for healing injuries, the same process could theoretically support the growth of existing tumors, which depend on new blood supply to expand. No studies have confirmed this risk, but it remains a plausible concern given the mechanism of action.
Why People Use It Anyway
BPC-157’s popularity exists in the gap between promising animal data and absent human proof. Athletes, biohackers, and people with chronic injuries or gut problems use it based on the animal research, anecdotal reports from online communities, and the logic that a peptide derived from the body’s own protective system should be relatively safe. Some integrative medicine practitioners recommend it for tendon injuries, joint pain, or gut inflammation.
The animal research profile is genuinely unusual. Few peptides show such broad effects across so many tissue types, from tendons and ligaments to brain tissue and gut lining. But “works in rats” is a notoriously unreliable predictor of what works in humans, and the absence of controlled human trials means that anyone using BPC-157 is essentially self-experimenting with an unregulated substance of uncertain purity.